FY2024 Earnings Estimate for IQVIA Issued By Leerink Partnrs

IQVIA Holdings Inc. (NYSE:IQV) – Investment analysts at Leerink Partnrs lowered their FY2024 earnings per share estimates for shares of IQVIA in a note issued to investors on Wednesday, October 23rd. Leerink Partnrs analyst M. Cherny now forecasts that the medical research company will earn $10.16 per share for the year, down from their previous forecast of $10.22. The consensus estimate for IQVIA’s current full-year earnings is $10.25 per share. Leerink Partnrs also issued estimates for IQVIA’s FY2025 earnings at $11.39 EPS, FY2026 earnings at $12.65 EPS and FY2027 earnings at $13.93 EPS.

IQV has been the topic of several other reports. Evercore ISI reduced their price objective on IQVIA from $270.00 to $265.00 and set an “outperform” rating on the stock in a report on Tuesday, October 8th. Truist Financial decreased their price objective on IQVIA from $300.00 to $286.00 and set a “buy” rating for the company in a report on Monday, October 14th. Argus upgraded shares of IQVIA to a “strong-buy” rating in a report on Wednesday, July 31st. Barclays reduced their price target on shares of IQVIA from $275.00 to $260.00 and set an “overweight” rating for the company in a report on Tuesday, October 15th. Finally, JPMorgan Chase & Co. cut their price objective on shares of IQVIA from $288.00 to $279.00 and set an “overweight” rating on the stock in a report on Wednesday, October 23rd. Four equities research analysts have rated the stock with a hold rating, thirteen have given a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $267.27.

IQVIA Stock Performance

IQVIA stock opened at $216.34 on Monday. The company has a debt-to-equity ratio of 1.80, a quick ratio of 0.85 and a current ratio of 0.85. The company has a market capitalization of $39.44 billion, a PE ratio of 28.10, a P/E/G ratio of 2.09 and a beta of 1.49. The company has a 50 day moving average price of $236.50 and a 200-day moving average price of $230.16. IQVIA has a fifty-two week low of $167.42 and a fifty-two week high of $261.73.

Insider Buying and Selling at IQVIA

In other news, insider Eric Sherbet sold 1,300 shares of the company’s stock in a transaction dated Tuesday, August 27th. The shares were sold at an average price of $246.33, for a total transaction of $320,229.00. Following the transaction, the insider now owns 19,536 shares in the company, valued at $4,812,302.88. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. 1.60% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On IQVIA

A number of large investors have recently made changes to their positions in IQV. Park Place Capital Corp purchased a new stake in IQVIA during the 3rd quarter valued at about $28,000. Versant Capital Management Inc increased its holdings in IQVIA by 733.3% in the 2nd quarter. Versant Capital Management Inc now owns 125 shares of the medical research company’s stock worth $26,000 after buying an additional 110 shares during the period. Opal Wealth Advisors LLC purchased a new position in IQVIA during the 2nd quarter worth approximately $27,000. Itau Unibanco Holding S.A. purchased a new position in IQVIA during the 2nd quarter worth approximately $29,000. Finally, International Assets Investment Management LLC acquired a new stake in IQVIA during the 2nd quarter valued at approximately $32,000. 89.62% of the stock is owned by hedge funds and other institutional investors.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.